sulofenur has been researched along with Methemoglobinemia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hall, KM; Molthrop, DC; Prchal, JT; Wheeler, RH | 1 |
| Brown, TD; Burris, HA; Cagnola, J; Craig, JB; Grindey, GB; Hamilton, JM; Havlin, K; Kuhn, JG; O'Rourke, TJ; Satterlee, WG | 1 |
| Alberts, DS; Grindey, GB; Hamilton, M; Matzner, M; McCloskey, TM; Peng, YM; Plezia, PM; Roe, DJ; Seitz, D; Taylor, CW | 1 |
| Grindey, G; Hainsworth, JD; Hamilton, M; Hande, KR; Jackson, L; Kuttesch, J; Satterlee, W | 1 |
| Greco, FA; Grindey, G; Hainsworth, JD; Hande, KR; Jackson, LE; Johnson, DH; Kuttesch, J; Satterlee, WG | 1 |
3 trial(s) available for sulofenur and Methemoglobinemia
| Article | Year |
|---|---|
Evaluation of the methemoglobinemia associated with sulofenur.
Topics: Antineoplastic Agents; Cytochrome Reductases; Cytochrome-B(5) Reductase; Humans; Methemoglobinemia; Sulfhemoglobin; Sulfonylurea Compounds | 1994 |
Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule.
Topics: Administration, Oral; Anemia; Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Hemolysis; Humans; Male; Methemoglobinemia; Middle Aged; Neoplasms; Sulfonylurea Compounds | 1994 |
Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Female; Humans; Methemoglobinemia; Middle Aged; Ovarian Neoplasms; Sulfonylurea Compounds | 1992 |
2 other study(ies) available for sulofenur and Methemoglobinemia
| Article | Year |
|---|---|
Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans.
Topics: Administration, Oral; Half-Life; Humans; Methemoglobinemia; Neoplasms; Sulfonylurea Compounds; Time Factors | 1990 |
Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641).
Topics: Antineoplastic Agents; Drug Evaluation; Female; Humans; Male; Methemoglobinemia; Middle Aged; Neoplasms; Sulfonylurea Compounds; Time Factors | 1989 |